A photograph of co-authors from the Division of Neurosurgery, Niigata College, together with Dr. Takuya Okada (center) and Dr. Manabu Natsumeda (proper of Dr. Okada). Credit score: Niigata College
A bunch led by the Division of Neurosurgery on the Mind Analysis Institute, Niigata College, has efficiently handled a affected person with a brainstem glioma harboring a uncommon IDH2 mutation. The case report was printed on-line within the journal Frontiers in Oncology.
The affected person initially offered with a gradual lack of listening to within the left ear, and MRI confirmed a lesion on the left facet of the brainstem, close to the basis exit zone of the left acoustic nerve.
Initially, a brainstem glioma with H3K27M mutation was suspected. Nevertheless, the gradual medical course and strange location of the brainstem glioma have been thought of atypical.
The affected person underwent magnetic resonance spectroscopy wherein 2-hydroxyglutarate, a marker for IDH mutation, was evident. Subsequently, the affected person underwent a surgical biopsy, and pathological evaluation revealed a uncommon IDH2 mutation.
Though most brainstem gliomas with H3K27M mutation have an unmethylated MGMT promoter and thus are immune to temozolomide, about 70% of IDH-mutant astrocytomas are identified to have a methylated MGMT promoter and are delicate to temozolomide.
A crew led by Dr. Manabu Natsumeda efficiently handled the affected person with temozolomide and radiation, and the tumor dramatically shrank, and surprisingly, the affected person’s listening to improved. The affected person has been off remedy after one 12 months of upkeep temozolomide remedy, however the tumor has not relapsed.
“We were fortunate to detect IDH mutation in this patient, or else we would not have used temozolomide. This case illustrates the importance of screening by MRS for IDH mutation and a safe biopsy to determine the optimal treatment,” explains Dr. Natsumeda.
Extra info:
Takuya Okada et al, Case Report: Improved listening to in a uncommon, grownup IDH2-mutant brainstem astrocytoma efficiently handled with radiation and temozolomide, Frontiers in Oncology (2025). DOI: 10.3389/fonc.2025.1555986
Offered by
Niigata College
Quotation:
Radiation and temozolomide improves listening to in an grownup brainstem glioma affected person with a uncommon IDH2 mutation: Case report (2025, July 17)
retrieved 17 July 2025
from https://medicalxpress.com/information/2025-07-temozolomide-adult-brainstem-glioma-patient.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
